{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:06Z","timestamp":1780750746172,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":138,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_2","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:00:18Z","timestamp":1753707618000},"page":"23-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution and Breakthroughs in Exon Skipping and Splice Modulation: From Inception to Clinical Success"],"prefix":"10.1007","author":[{"given":"Kenji Rowel Q.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0092-8674(77)90180-5","volume":"12","author":"LT Chow","year":"1977","unstructured":"Chow LT, Gelinas RE, Broker TR, Roberts RJ (1977) An amazing sequence arrangement at the 5\u2032 ends of adenovirus 2 messenger RNA. Cell 12:1\u20138","journal-title":"Cell"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1073\/pnas.74.8.3171","volume":"74","author":"SM Berget","year":"1977","unstructured":"Berget SM, Moore C, Sharp PA (1977) Spliced segments at the 5\u2032 terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci USA 74:3171\u20133175. https:\/\/doi.org\/10.1073\/pnas.74.8.3171","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"ENCODE Project Consortium","year":"2012","unstructured":"ENCODE Project Consortium (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57\u201374. https:\/\/doi.org\/10.1038\/nature11247","journal-title":"Nature"},{"key":"2_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrg2776","volume":"11","author":"H Keren","year":"2010","unstructured":"Keren H, Lev-Maor G, Ast G (2010) Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 11:345\u2013355. https:\/\/doi.org\/10.1038\/nrg2776","journal-title":"Nat Rev Genet"},{"key":"2_CR5","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nature07509","volume":"456","author":"ET Wang","year":"2008","unstructured":"Wang ET, Sandberg R, Luo S et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470\u2013476. https:\/\/doi.org\/10.1038\/nature07509","journal-title":"Nature"},{"key":"2_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/ng.259","volume":"40","author":"Q Pan","year":"2008","unstructured":"Pan Q, Shai O, Lee LJ et al (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40:1413\u20131415. https:\/\/doi.org\/10.1038\/ng.259","journal-title":"Nat Genet"},{"key":"2_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/humu.20400","volume":"28","author":"M Krawczak","year":"2007","unstructured":"Krawczak M, Thomas NST, Hundrieser B et al (2007) Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 28:150\u2013158. https:\/\/doi.org\/10.1002\/humu.20400","journal-title":"Hum Mutat"},{"key":"2_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/bfgp\/elr020","volume":"10","author":"AGL Douglas","year":"2011","unstructured":"Douglas AGL, Wood MJA (2011) RNA splicing: disease and therapy. Brief Funct Genomics 10:151\u2013164. https:\/\/doi.org\/10.1093\/bfgp\/elr020","journal-title":"Brief Funct Genomics"},{"key":"2_CR9","doi-asserted-by":"publisher","first-page":"9362","DOI":"10.1073\/pnas.0903103106","volume":"106","author":"L Hindorff","year":"2009","unstructured":"Hindorff L et al (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 106:9362\u20139367. https:\/\/doi.org\/10.1073\/pnas.0903103106","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR10","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.febslet.2005.02.047","volume":"579","author":"N L\u00f3pez-Bigas","year":"2005","unstructured":"L\u00f3pez-Bigas N, Audit B, Ouzounis C et al (2005) Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 579:1900\u20131903. https:\/\/doi.org\/10.1016\/j.febslet.2005.02.047","journal-title":"FEBS Lett"},{"key":"2_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1201\/9780849387951.ch4","volume-title":"Antisense drug technology","author":"P Sazani","year":"2007","unstructured":"Sazani P, Graziewicz M, Kole R (2007) Splice switching oligonucleotides as potential therapeutics. In: Antisense drug technology. CRC Press, pp 89\u2013114"},{"key":"2_CR12","volume-title":"Garland science","author":"B Alberts","year":"2008","unstructured":"Alberts B, Johnson A, Lewis J et al (2008) Molecular biology of the cell. In: Garland science, 5th edn. Taylor & Francis Group, New York","edition":"5"},{"key":"2_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrm2777","volume":"10","author":"M Chen","year":"2009","unstructured":"Chen M, Manley JL (2009) Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10:741\u2013754. https:\/\/doi.org\/10.1038\/nrm2777","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrg.2015.3","volume":"17","author":"MM Scotti","year":"2016","unstructured":"Scotti MM, Swanson MS (2016) RNA mis-splicing in disease. Nat Rev Genet 17:19\u201332. https:\/\/doi.org\/10.1038\/nrg.2015.3","journal-title":"Nat Rev Genet"},{"key":"2_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/wrna.1141","volume":"4","author":"JJ Turunen","year":"2013","unstructured":"Turunen JJ, Niemel\u00e4 EH, Verma B, Frilander MJ (2013) The significant other: splicing by the minor spliceosome. Wiley Interdiscip Rev RNA 4:61\u201376. https:\/\/doi.org\/10.1002\/wrna.1141","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"2_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1001016","volume":"6","author":"A Corvelo","year":"2010","unstructured":"Corvelo A, Hallegger M, Smith CWJ, Eyras E (2010) Genome-wide association between branch point properties and alternative splicing. PLoS Comput Biol 6:e1001016. https:\/\/doi.org\/10.1371\/journal.pcbi.1001016","journal-title":"PLoS Comput Biol"},{"key":"2_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.tibs.2008.04.004","volume":"33","author":"MJ Schellenberg","year":"2008","unstructured":"Schellenberg MJ, Ritchie DB, MacMillan AM (2008) Pre-mRNA splicing: a complex picture in higher definition. Trends Biochem Sci 33:243\u2013246. https:\/\/doi.org\/10.1016\/j.tibs.2008.04.004","journal-title":"Trends Biochem Sci"},{"key":"2_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/nar\/25.4.888","volume":"25","author":"CJ Coolidge","year":"1997","unstructured":"Coolidge CJ, Seely RJ, Patton JG (1997) Functional analysis of the polypyrimidine tract in pre-mRNA splicing. Nucleic Acids Res 25:888\u2013896. https:\/\/doi.org\/10.1093\/nar\/25.4.888","journal-title":"Nucleic Acids Res"},{"key":"2_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75:285\u2013288. https:\/\/doi.org\/10.1073\/pnas.75.1.285","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1073\/pnas.75.1.280","volume":"75","author":"PC Zamecnik","year":"1978","unstructured":"Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75:280\u2013284. https:\/\/doi.org\/10.1073\/pnas.75.1.280","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/nar\/7.1.179","volume":"7","author":"H Donis-Keller","year":"1979","unstructured":"Donis-Keller H (1979) Site specific enzymatic cleavage of RNA. Nucleic Acids Res 7:179\u2013192. https:\/\/doi.org\/10.1093\/nar\/7.1.179","journal-title":"Nucleic Acids Res"},{"key":"2_CR22","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/j.1460-2075.1988.tb03100.x","volume":"7","author":"SH Munroe","year":"1988","unstructured":"Munroe SH (1988) Antisense RNA inhibits splicing of pre-mRNA in vitro. EMBO J 7:2523\u20132532","journal-title":"EMBO J"},{"key":"2_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/oxfordjournals.jbchem.a123213","volume":"108","author":"A Mayeda","year":"1990","unstructured":"Mayeda A, Hayase Y, Inoue H et al (1990) Surveying cis-acting sequences of pre-mRNA by adding antisense 2\u2019-O-methyl oligoribonucleotides to a splicing reaction. J Biochem 108:399\u2013405","journal-title":"J Biochem"},{"key":"2_CR24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1021\/ja01033a054","volume":"91","author":"AM Bobst","year":"1969","unstructured":"Bobst AM, Cerutti PA, Rottman F (1969) Structure of poly(2\u2019-O-methyladenylic acid) at acidic and neutral pH. J Am Chem Soc 91:1246\u20131248. https:\/\/doi.org\/10.1021\/ja01033a054","journal-title":"J Am Chem Soc"},{"key":"2_CR25","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1093\/nar\/15.15.6131","volume":"15","author":"H Inoue","year":"1987","unstructured":"Inoue H, Hayase Y, Imura A et al (1987) Synthesis and hybridization studies on two complementary nona(2\u2019-O-methyl)ribonucleotides. Nucleic Acids Res 15:6131\u20136148. https:\/\/doi.org\/10.1093\/nar\/15.15.6131","journal-title":"Nucleic Acids Res"},{"key":"2_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0014-5793(87)80171-0","volume":"215","author":"H Inoue","year":"1987","unstructured":"Inoue H, Hayase Y, Iwai S, Ohtsuka E (1987) Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. Nucleic Acids Symp Ser 215:221\u2013224. https:\/\/doi.org\/10.1016\/0014-5793(87)80171-0","journal-title":"Nucleic Acids Symp Ser"},{"key":"2_CR27","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1021\/ar00057a002","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski Z, Kole R (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 90:8673\u20138677. https:\/\/doi.org\/10.1021\/ar00057a002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR28","doi-asserted-by":"publisher","first-page":"a011700","DOI":"10.1101\/cshperspect.a011700","volume":"3","author":"SL Thein","year":"2013","unstructured":"Thein SL (2013) The molecular basis of b-thalassemia. Cold Spring Harb Perspect Med 3:a011700\u2013a011700. https:\/\/doi.org\/10.1101\/cshperspect.a011700","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2_CR29","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1021\/ja00970a054","volume":"88","author":"F Eckstein","year":"1966","unstructured":"Eckstein F (1966) Nucleoside Phosphorothioates. J Am Chem Soc 88:4292\u20134294. https:\/\/doi.org\/10.1021\/ja00970a054","journal-title":"J Am Chem Soc"},{"key":"2_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/oli.1.2000.10.117","volume":"10","author":"F Eckstein","year":"2000","unstructured":"Eckstein F (2000) Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev 10:117\u2013121. https:\/\/doi.org\/10.1089\/oli.1.2000.10.117","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"2_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt.3802","volume":"35","author":"SF Dowdy","year":"2017","unstructured":"Dowdy SF (2017) Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35:222\u2013229. https:\/\/doi.org\/10.1038\/nbt.3802","journal-title":"Nat Biotechnol"},{"key":"2_CR32","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1021\/bi00590a017","volume":"18","author":"PS Miller","year":"1979","unstructured":"Miller PS, Yano J, Yano E et al (1979) Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. Biochemistry 18:5134\u20135143","journal-title":"Biochemistry"},{"key":"2_CR33","doi-asserted-by":"publisher","first-page":"12840","DOI":"10.1073\/pnas.93.23.12840","volume":"93","author":"H Sierakowska","year":"1996","unstructured":"Sierakowska H, Sambade MJ, Agrawal S, Kole R (1996) Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 93:12840\u201312844. https:\/\/doi.org\/10.1073\/pnas.93.23.12840","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR34","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/07328319708006154","volume":"16","author":"H Sierakowska","year":"1997","unstructured":"Sierakowska H, Montague M, Agrawal S, Kole R (1997) Restoration of \u00df-globin gene expression in mammalian cells by antisense oligonucleotides that modify the aberrant splicing Patierns of Thalassemic pre-mRNAs. Nucleosides Nucleotides 16:1173\u20131182. https:\/\/doi.org\/10.1080\/07328319708006154","journal-title":"Nucleosides Nucleotides"},{"key":"2_CR35","doi-asserted-by":"publisher","first-page":"36193","DOI":"10.1074\/jbc.274.51.36193","volume":"274","author":"KJ Friedman","year":"1999","unstructured":"Friedman KJ, Kole J, Cohn JA et al (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 274:36193\u201336199. https:\/\/doi.org\/10.1074\/jbc.274.51.36193","journal-title":"J Biol Chem"},{"key":"2_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm1204","volume":"11","author":"P Scaffidi","year":"2005","unstructured":"Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11:440\u2013445. https:\/\/doi.org\/10.1038\/nm1204","journal-title":"Nat Med"},{"key":"2_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/humu.20303","volume":"27","author":"F Vetrini","year":"2006","unstructured":"Vetrini F, Tammaro R, Bondanza S et al (2006) Aberrant splicing in the ocular albinism type 1 gene (OA1\/GPR143) is corrected in vitro by morpholino antisense oligonucleotides. Hum Mutat 27:420\u2013426. https:\/\/doi.org\/10.1002\/humu.20303","journal-title":"Hum Mutat"},{"key":"2_CR38","unstructured":"U.S. Food and Drug Administration (2016) FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm521263.htm. Accessed 30 Aug 2017"},{"key":"2_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AEH Emery","year":"1991","unstructured":"Emery AEH (1991) Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1:19\u201329","journal-title":"Neuromuscul Disord"},{"key":"2_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304\u2013313. https:\/\/doi.org\/10.1002\/ana.23528","journal-title":"Ann Neurol"},{"key":"2_CR41","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/adc.2007.118141","volume":"93","author":"A Manzur","year":"2008","unstructured":"Manzur A, Kinali M, Muntoni F (2008) Update on the management of Duchenne muscular dystrophy. Arch Dis Child 93:986\u2013990. https:\/\/doi.org\/10.1136\/adc.2007.118141","journal-title":"Arch Dis Child"},{"key":"2_CR42","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"key":"2_CR43","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof BJ, Shrager JB, Stedman HH et al (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 90:3710\u20133714. https:\/\/doi.org\/10.1073\/pnas.90.8.3710","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","volume":"50","author":"M Koenig","year":"1987","unstructured":"Koenig M, Hoffman EP, Bertelson CJ et al (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50:509\u2013517. https:\/\/doi.org\/10.1016\/0092-8674(87)90504-6","journal-title":"Cell"},{"key":"2_CR45","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1006\/geno.1993.1225","volume":"16","author":"RG Roberts","year":"1993","unstructured":"Roberts RG, Coffey AJ, Bobrow M, Bentley DR (1993) Exon structure of the human dystrophin gene. Genomics 16:536\u2013538. https:\/\/doi.org\/10.1006\/geno.1993.1225","journal-title":"Genomics"},{"key":"2_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90\u201395. https:\/\/doi.org\/10.1016\/0888-7543(88)90113-9","journal-title":"Genomics"},{"key":"2_CR47","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498\u2013506","journal-title":"Am J Hum Genet"},{"key":"2_CR48","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/0006-291X(90)92185-3","volume":"170","author":"M Matsuo","year":"1990","unstructured":"Matsuo M, Masumura T, Nakajima T et al (1990) A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene. Biochem Biophys Res Commun 170:963\u2013967","journal-title":"Biochem Biophys Res Commun"},{"key":"2_CR49","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1172\/JCI115244","volume":"87","author":"M Matsuo","year":"1991","unstructured":"Matsuo M, Masumura T, Nishio H et al (1991) Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe. J Clin Invest 87:2127\u20132131. https:\/\/doi.org\/10.1172\/JCI115244","journal-title":"J Clin Invest"},{"key":"2_CR50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI117693","volume":"95","author":"Y Takeshima","year":"1995","unstructured":"Takeshima Y, Nishio H, Sakamoto H et al (1995) Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe. J Clin Invest 95:515\u2013520. https:\/\/doi.org\/10.1172\/JCI117693","journal-title":"J Clin Invest"},{"key":"2_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0022-510X(89)90224-4","volume":"94","author":"LVB Nicholson","year":"1989","unstructured":"Nicholson LVB, Davison K, Johnson MA et al (1989) Dystrophin in skeletal muscle II. Immunoreactivity in patients with Xp21 muscular dystrophy. J Neurol Sci 94:137\u2013146. https:\/\/doi.org\/10.1016\/0022-510X(89)90224-4","journal-title":"J Neurol Sci"},{"key":"2_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0022-510X(90)90195-S","volume":"99","author":"EP Hoffman","year":"1990","unstructured":"Hoffman EP, Morgan JE, Watkins SC, Partridge TA (1990) Somatic reversion\/suppression of the mouse mdx phenotype in vivo. J Neurol Sci 99:9\u201325. https:\/\/doi.org\/10.1016\/0022-510X(90)90195-S","journal-title":"J Neurol Sci"},{"key":"2_CR53","first-page":"950","volume":"50","author":"CJ Klein","year":"1992","unstructured":"Klein CJ, Coovert DD, Bulman DE et al (1992) Somatic reversion\/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 50:950\u2013959","journal-title":"Am J Hum Genet"},{"key":"2_CR54","first-page":"725","volume":"56","author":"LT Thanh","year":"1995","unstructured":"Thanh LT, Nguyen TM, Helliwell TR, Morris GE (1995) Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am J Hum Genet 56:725\u2013731","journal-title":"Am J Hum Genet"},{"key":"2_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069194","volume":"8","author":"Y Echigoya","year":"2013","unstructured":"Echigoya Y, Lee J, Rodrigues M et al (2013) Mutation types and aging differently affect Revertant fiber expansion in dystrophic mdx and Mdx52 mice. PLoS One 8:e69194. https:\/\/doi.org\/10.1371\/journal.pone.0069194","journal-title":"PLoS One"},{"key":"2_CR56","doi-asserted-by":"publisher","unstructured":"Rodrigues M, Echigoya Y, Maruyama R et al (2016) Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA\/2 background. Sci Rep 6. https:\/\/doi.org\/10.1038\/srep38371","DOI":"10.1038\/srep38371"},{"key":"2_CR57","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","volume":"226","author":"ZA Pramono","year":"1996","unstructured":"Pramono ZA, Takeshima Y, Alimsardjono H et al (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 226:445\u2013449","journal-title":"Biochem Biophys Res Commun"},{"key":"2_CR58","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1126\/science.2662404","volume":"244","author":"P Sicinski","year":"1989","unstructured":"Sicinski P, Geng Y, Ryder-Cook AS et al (1989) The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244:1578\u20131580","journal-title":"Science"},{"key":"2_CR59","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/hmg\/7.7.1083","volume":"7","author":"MG Dunckley","year":"1998","unstructured":"Dunckley MG, Manoharan M, Villiet P et al (1998) Modification of splicing in the dystrophin gene in cultured mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 7:1083\u20131090","journal-title":"Hum Mol Genet"},{"key":"2_CR60","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S0960-8966(99)00010-3","volume":"9","author":"SD Wilton","year":"1999","unstructured":"Wilton SD, Lloyd F, Carville K et al (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 9:330\u2013338. https:\/\/doi.org\/10.1016\/S0960-8966(99)00010-3","journal-title":"Neuromuscul Disord"},{"key":"2_CR61","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/HMG\/10.15.1547","volume":"10","author":"JC van Deutekom","year":"2001","unstructured":"van Deutekom JC, Bremmer-Bout M, Janson AA et al (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10:1547\u20131554. https:\/\/doi.org\/10.1093\/HMG\/10.15.1547","journal-title":"Hum Mol Genet"},{"key":"2_CR62","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0387-7604(01)00326-6","volume":"23","author":"Y Takeshima","year":"2001","unstructured":"Takeshima Y, Wada H, Yagi M et al (2001) Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev 23:788\u2013790. https:\/\/doi.org\/10.1016\/S0387-7604(01)00326-6","journal-title":"Brain Dev"},{"key":"2_CR63","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/hmg\/ddg100","volume":"12","author":"A Aartsma-Rus","year":"2003","unstructured":"Aartsma-Rus A, Janson AAM, Kaman WE et al (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12:907\u2013914","journal-title":"Hum Mol Genet"},{"key":"2_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1086\/381039","volume":"74","author":"A Aartsma-Rus","year":"2004","unstructured":"Aartsma-Rus A, Janson A et al (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74:83\u201392. https:\/\/doi.org\/10.1086\/381039","journal-title":"Am J Hum Genet"},{"key":"2_CR65","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.gt.3302313","volume":"11","author":"A Aartsma-Rus","year":"2004","unstructured":"Aartsma-Rus A, Kaman WE, Bremmer-Bout M et al (2004) Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther 11:1391\u20131398. https:\/\/doi.org\/10.1038\/sj.gt.3302313","journal-title":"Gene Ther"},{"key":"2_CR66","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/1043034041648444","volume":"15","author":"A Surono","year":"2004","unstructured":"Surono A, Van Khanh T, Takeshima Y et al (2004) Chimeric RNA\/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. Hum Gene Ther 15:749\u2013757. https:\/\/doi.org\/10.1089\/1043034041648444","journal-title":"Hum Gene Ther"},{"key":"2_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2350-8-43","volume":"8","author":"A Aartsma-Rus","year":"2007","unstructured":"Aartsma-Rus A, Janson AAM, van Ommen G-JB, van Deutekom JCT (2007) Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 8:43. https:\/\/doi.org\/10.1186\/1471-2350-8-43","journal-title":"BMC Med Genet"},{"key":"2_CR68","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1073\/pnas.011408598","volume":"98","author":"CJ Mann","year":"2001","unstructured":"Mann CJ, Honeyman K, Cheng AJ et al (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 98:42\u201347. https:\/\/doi.org\/10.1073\/pnas.011408598","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR69","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm897","volume":"9","author":"QL Lu","year":"2003","unstructured":"Lu QL, Mann CJ, Lou F et al (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9:1009\u20131014. https:\/\/doi.org\/10.1038\/nm897","journal-title":"Nat Med"},{"key":"2_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6817-6_1","volume":"1565","author":"JE Summerton","year":"2017","unstructured":"Summerton JE (2017) Invention and early history of Morpholinos: from pipe dream to practical products. Methods Mol Biol 1565:1\u201315. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_1","journal-title":"Methods Mol Biol"},{"key":"2_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","volume":"7","author":"J Summerton","year":"1997","unstructured":"Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187\u2013195. https:\/\/doi.org\/10.1089\/oli.1.1997.7.187","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"2_CR72","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJA Lee","year":"2013","unstructured":"Lee JJA, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3:144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"key":"2_CR73","first-page":"1023","volume":"3","author":"JD Moulton","year":"2016","unstructured":"Moulton JD (2016) Guide for morpholino users: toward therapeutics. J Drug Discov Dev Deliv 3:1023","journal-title":"J Drug Discov Dev Deliv"},{"key":"2_CR74","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","volume":"12","author":"BL Gebski","year":"2003","unstructured":"Gebski BL, Mann CJ, Fletcher S, Wilton SD (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12:1801\u20131811. https:\/\/doi.org\/10.1093\/hmg\/ddg196","journal-title":"Hum Mol Genet"},{"key":"2_CR75","doi-asserted-by":"publisher","first-page":"21783","DOI":"10.1074\/jbc.274.31.21783","volume":"274","author":"G Schmajuk","year":"1999","unstructured":"Schmajuk G, Sierakowska H, Kole R (1999) Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J Biol Chem 274:21783\u201321789","journal-title":"J Biol Chem"},{"key":"2_CR76","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1073\/pnas.97.17.9591","volume":"97","author":"G Lacerra","year":"2000","unstructured":"Lacerra G, Sierakowska H, Carestia C et al (2000) Restoration of hemoglobin a synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci 97:9591\u20139596. https:\/\/doi.org\/10.1073\/pnas.97.17.9591","journal-title":"Proc Natl Acad Sci"},{"key":"2_CR77","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1124\/mol.62.3.545","volume":"62","author":"T Suwanmanee","year":"2002","unstructured":"Suwanmanee T, Sierakowska H, Lacerra G et al (2002) Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol 62:545\u2013553","journal-title":"Mol Pharmacol"},{"key":"2_CR78","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1006\/mthe.2002.0805","volume":"6","author":"T Suwanmanee","year":"2002","unstructured":"Suwanmanee T, Sierakowska H, Fucharoen S, Kole R (2002) Repair of a splicing defect in erythroid cells from patients with beta-thalassemia\/HbE disorder. Mol Ther 6:718\u2013726","journal-title":"Mol Ther"},{"key":"2_CR79","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0014-5793(03)00904-9","volume":"552","author":"KE Wells","year":"2003","unstructured":"Wells KE, Fletcher S, Mann CJ et al (2003) Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett 552:145\u2013149","journal-title":"FEBS Lett"},{"key":"2_CR80","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/jgm.603","volume":"6","author":"IR Graham","year":"2004","unstructured":"Graham IR, Hill VJ, Manoharan M et al (2004) Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med 6:1149\u20131158. https:\/\/doi.org\/10.1002\/jgm.603","journal-title":"J Gene Med"},{"key":"2_CR81","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm1345","volume":"12","author":"J Alter","year":"2006","unstructured":"Alter J, Lou F, Rabinowitz A et al (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175\u2013177. https:\/\/doi.org\/10.1038\/nm1345","journal-title":"Nat Med"},{"key":"2_CR83","first-page":"1314","volume":"7","author":"X Yu","year":"2015","unstructured":"Yu X, Bao B, Echigoya Y, Yokota T (2015) Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res 7:1314\u20131331","journal-title":"Am J Transl Res"},{"key":"2_CR84","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1538\/expanim.52.93","volume":"52","author":"Y Shimatsu","year":"2003","unstructured":"Shimatsu Y, Katagiri K, Furuta T et al (2003) Canine X-linked muscular dystrophy in Japan (CXMDJ). Exp Anim 52:93\u201397","journal-title":"Exp Anim"},{"key":"2_CR85","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/ana.21627","volume":"65","author":"T Yokota","year":"2009","unstructured":"Yokota T, Lu Q-L, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667\u2013676. https:\/\/doi.org\/10.1002\/ana.21627","journal-title":"Ann Neurol"},{"key":"2_CR86","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/sj.gt.3302800","volume":"13","author":"G McClorey","year":"2006","unstructured":"McClorey G, Moulton HM, Iversen PL et al (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13:1373\u20131381. https:\/\/doi.org\/10.1038\/sj.gt.3302800","journal-title":"Gene Ther"},{"key":"2_CR87","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1203\/01.pdr.0000215047.51278.7c","volume":"59","author":"Y Takeshima","year":"2006","unstructured":"Takeshima Y, Yagi M, Wada H et al (2006) Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 59:690\u2013694. https:\/\/doi.org\/10.1203\/01.pdr.0000215047.51278.7c","journal-title":"Pediatr Res"},{"key":"2_CR88","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1056\/NEJMoa073108","volume":"357","author":"JC van Deutekom","year":"2007","unstructured":"van Deutekom JC, Janson AA, Ginjaar IB et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677\u20132686. https:\/\/doi.org\/10.1056\/NEJMoa073108","journal-title":"N Engl J Med"},{"key":"2_CR89","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","volume":"8","author":"M Kinali","year":"2009","unstructured":"Kinali M, Arechavala-Gomeza V, Feng L et al (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918\u2013928. https:\/\/doi.org\/10.1016\/S1474-4422(09)70211-X","journal-title":"Lancet Neurol"},{"key":"2_CR90","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"key":"2_CR91","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J (2016) Approving a problematic muscular dystrophy drug: implications for FDA policy. JAMA 316:2357\u20132358. https:\/\/doi.org\/10.1001\/jama.2016.16437","journal-title":"JAMA"},{"key":"2_CR92","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQKRQ Lim","year":"2017","unstructured":"Lim KRQKRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"key":"2_CR93","unstructured":"U.S. Food and Drug Administration: Center for Drug Evaluation and Research (2016) Summary review, application number: 206488Orig1s000. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206488_summary review_Redacted.pdf. Accessed 30 Aug 2017"},{"key":"2_CR94","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25:2561. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"key":"2_CR95","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7:1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"key":"2_CR96","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","volume":"56","author":"S Anwar","year":"2020","unstructured":"Anwar S, Yokota T (2020) Golodirsen for Duchenne muscular dystrophy. Drugs Today 56:491\u2013504. https:\/\/doi.org\/10.1358\/dot.2020.56.8.3159186","journal-title":"Drugs Today"},{"key":"2_CR97","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","volume":"55","author":"RR Roshmi","year":"2019","unstructured":"Roshmi RR, Yokota T (2019) Viltolarsen for the treatment of Duchenne muscular dystrophy. Drugs Today 55:627. https:\/\/doi.org\/10.1358\/dot.2019.55.10.3045038","journal-title":"Drugs Today"},{"key":"2_CR98","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","volume":"57","author":"H Wilton-Clark","year":"2021","unstructured":"Wilton-Clark H, Yokota T (2021) Casimersen for Duchenne muscular dystrophy. Drugs Today (Barc) 57:707\u2013717. https:\/\/doi.org\/10.1358\/dot.2021.57.12.3352740","journal-title":"Drugs Today (Barc)"},{"key":"2_CR99","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/15079","volume":"17","author":"JK Taylor","year":"1999","unstructured":"Taylor JK, Zhang QQ, Wyatt JR, Dean NM (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 17:1097\u20131100. https:\/\/doi.org\/10.1038\/15079","journal-title":"Nat Biotechnol"},{"key":"2_CR100","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hlca.19950780219","volume":"78","author":"P Martin","year":"1995","unstructured":"Martin P (1995) Ein neuer Zugang zu 2\u2019-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide. Helv Chim Acta 78:486\u2013504. https:\/\/doi.org\/10.1002\/hlca.19950780219","journal-title":"Helv Chim Acta"},{"key":"2_CR101","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0925-4439(02)00075-3","volume":"1587","author":"DR Mercatante","year":"2002","unstructured":"Mercatante DR, Kole R (2002) Control of alternative splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochim Biophys Acta 1587:126\u2013132. https:\/\/doi.org\/10.1016\/S0925-4439(02)00075-3","journal-title":"Biochim Biophys Acta"},{"key":"2_CR102","doi-asserted-by":"publisher","first-page":"16411","DOI":"10.1074\/jbc.M009256200","volume":"276","author":"DR Mercatante","year":"2001","unstructured":"Mercatante DR, Bortner CD, Cidlowski JA, Kole R (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. Analysis of apoptosis and cell death. J Biol Chem 276:16411\u201316417. https:\/\/doi.org\/10.1074\/jbc.M009256200","journal-title":"J Biol Chem"},{"key":"2_CR103","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1046\/j.1523-1747.1999.00709.x","volume":"113","author":"JA McGrath","year":"1999","unstructured":"McGrath JA, Ashton GHS, Mellerio JE et al (1999) Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. J Invest Dermatol 113:314\u2013321. https:\/\/doi.org\/10.1046\/j.1523-1747.1999.00709.x","journal-title":"J Invest Dermatol"},{"key":"2_CR104","doi-asserted-by":"publisher","first-page":"42986","DOI":"10.1074\/jbc.M105113200","volume":"276","author":"B Kalbfuss","year":"2001","unstructured":"Kalbfuss B, Mabon SA, Misteli T (2001) Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 276:42986\u201342993. https:\/\/doi.org\/10.1074\/jbc.M105113200","journal-title":"J Biol Chem"},{"key":"2_CR105","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1158\/1535-7163.1467.3.11","volume":"3","author":"J Renshaw","year":"2004","unstructured":"Renshaw J, Orr RM, Walton MI et al (2004) Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol Cancer Ther 3:1467\u20131484","journal-title":"Mol Cancer Ther"},{"key":"2_CR106","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/genes8060161","volume":"8","author":"KEKE Meijboom","year":"2017","unstructured":"Meijboom KEKE, Wood MJAA, McClorey G (2017) Splice-switching therapy for spinal muscular atrophy. Genes (Basel) 8:161. https:\/\/doi.org\/10.3390\/genes8060161","journal-title":"Genes (Basel)"},{"key":"2_CR107","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT (2015) Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51:157\u2013167. https:\/\/doi.org\/10.1002\/mus.24497","journal-title":"Muscle Nerve"},{"key":"2_CR108","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1086\/302369","volume":"64","author":"B Wirth","year":"1999","unstructured":"Wirth B, Herz M, Wetter A et al (1999) Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet 64:1340\u20131356. https:\/\/doi.org\/10.1086\/302369","journal-title":"Am J Hum Genet"},{"key":"2_CR109","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","volume":"4","author":"MD Mailman","year":"2002","unstructured":"Mailman MD, Heinz JW, Papp AC et al (2002) Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 4:20\u201326. https:\/\/doi.org\/10.1097\/00125817-200201000-00004","journal-title":"Genet Med"},{"key":"2_CR110","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96:6307\u20136311","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR111","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","volume":"8","author":"UR Monani","year":"1999","unstructured":"Monani UR, Lorson CL, Parsons DW et al (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8:1177\u20131183","journal-title":"Hum Mol Genet"},{"key":"2_CR112","doi-asserted-by":"publisher","first-page":"45476","DOI":"10.1074\/jbc.M107632200","volume":"276","author":"SR Lim","year":"2001","unstructured":"Lim SR, Hertel KJ (2001) Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3\u2032 splice site pairing. J Biol Chem 276:45476\u201345483. https:\/\/doi.org\/10.1074\/jbc.M107632200","journal-title":"J Biol Chem"},{"key":"2_CR113","doi-asserted-by":"publisher","first-page":"23271","DOI":"10.1074\/jbc.M200851200","volume":"277","author":"H Miyajima","year":"2002","unstructured":"Miyajima H, Miyaso H, Okumura M et al (2002) Identification of a cis-acting element for the regulation of SMN exon 7 splicing. J Biol Chem 277:23271\u201323277. https:\/\/doi.org\/10.1074\/jbc.M200851200","journal-title":"J Biol Chem"},{"key":"2_CR114","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1073\/pnas.0633863100","volume":"100","author":"LA Skordis","year":"2003","unstructured":"Skordis LA, Dunckley MG, Yue B et al (2003) Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci USA 100:4114\u20134119. https:\/\/doi.org\/10.1073\/pnas.0633863100","journal-title":"Proc Natl Acad Sci USA"},{"key":"2_CR115","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1038\/s41598-017-03850-2","volume":"7","author":"A Touznik","year":"2017","unstructured":"Touznik A, Maruyama R, Hosoki K et al (2017) LNA\/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts. Sci Rep 7:3672. https:\/\/doi.org\/10.1038\/s41598-017-03850-2","journal-title":"Sci Rep"},{"key":"2_CR116","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK, Singh NN, Androphy EJ, Singh RN (2006) Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26:1333\u20131346. https:\/\/doi.org\/10.1128\/MCB.26.4.1333-1346.2006","journal-title":"Mol Cell Biol"},{"key":"2_CR117","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","volume":"82","author":"Y Hua","year":"2008","unstructured":"Hua Y, Vickers TA, Okunola HL et al (2008) Antisense masking of an hnRNP A1\/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82:834\u2013848. https:\/\/doi.org\/10.1016\/j.ajhg.2008.01.014","journal-title":"Am J Hum Genet"},{"key":"2_CR118","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1101\/gad.1941310","volume":"24","author":"Y Hua","year":"2010","unstructured":"Hua Y, Sahashi K, Hung G et al (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24:1634\u20131644. https:\/\/doi.org\/10.1101\/gad.1941310","journal-title":"Genes Dev"},{"key":"2_CR119","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA, Bu J, Richards AM et al (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3:72ra18. https:\/\/doi.org\/10.1126\/scitranslmed.3001777","journal-title":"Sci Transl Med"},{"key":"2_CR120","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT et al (2016) Results from a phase 1 study of nusinersen (ISIS-SMN Rx) in children with spinal muscular atrophy. Neurology 86:890\u2013897. https:\/\/doi.org\/10.1212\/WNL.0000000000002445","journal-title":"Neurology"},{"key":"2_CR121","unstructured":"U.S. Food and Drug Administration (2016) FDA approves first drug for spinal muscular atrophy. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm. Accessed 29 Nov 2017"},{"key":"2_CR122","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1021\/mp900093r","volume":"6","author":"R Juliano","year":"2009","unstructured":"Juliano R, Bauman J, Kang H, Ming X (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6:686\u2013695. https:\/\/doi.org\/10.1021\/mp900093r","journal-title":"Mol Pharm"},{"key":"2_CR123","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35:238\u2013248. https:\/\/doi.org\/10.1038\/nbt.3765","journal-title":"Nat Biotechnol"},{"key":"2_CR124","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1962210","volume":"254","author":"PE Nielsen","year":"1991","unstructured":"Nielsen PE, Egholm M, Berg RH, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254:1497\u20131500","journal-title":"Science"},{"key":"2_CR125","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1016\/S0040-4020(98)00094-5","volume":"54","author":"AA Koshkin","year":"1998","unstructured":"Koshkin AA, Singh SK, Nielsen P et al (1998) LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 54:3607\u20133630. https:\/\/doi.org\/10.1016\/S0040-4020(98)00094-5","journal-title":"Tetrahedron"},{"key":"2_CR126","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1016\/S0040-4039(98)01084-3","volume":"39","author":"S Obika","year":"1998","unstructured":"Obika S, Nanbu D, Hari Y et al (1998) Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2\u2032-O,4\u2032-C-methyleneribonucleosides. Tetrahedron Lett 39:5401\u20135404. https:\/\/doi.org\/10.1016\/S0040-4039(98)01084-3","journal-title":"Tetrahedron Lett"},{"key":"2_CR127","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1021\/ja983570w","volume":"121","author":"R Steffens","year":"1999","unstructured":"Steffens R, Leumann CJ (1999) Synthesis and thermodynamic and biophysical properties of Tricyclo-DNA. J Am Chem Soc 121:3249\u20133255. https:\/\/doi.org\/10.1021\/ja983570w","journal-title":"J Am Chem Soc"},{"key":"2_CR128","first-page":"553","volume-title":"Nucleic acids symposium series","author":"PP Seth","year":"2008","unstructured":"Seth PP, Siwkowski A, Allerson CR et al (2008) Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. In: Nucleic acids symposium series, vol 52. Oxford University Press, pp 553\u2013554"},{"key":"2_CR129","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","volume":"1798","author":"HM Moulton","year":"2010","unstructured":"Moulton HM, Moulton JD (2010) Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta Biomembr 1798:2296\u20132303. https:\/\/doi.org\/10.1016\/j.bbamem.2010.02.012","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"2_CR130","first-page":"123","volume":"5","author":"HM Moulton","year":"2003","unstructured":"Moulton HM, Moulton JD (2003) Peptide-assisted delivery of steric-blocking antisense oligomers. Curr Opin Mol Ther 5:123\u2013132","journal-title":"Curr Opin Mol Ther"},{"key":"2_CR131","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci 114:4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci"},{"key":"2_CR132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120058","volume":"10","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Mouly V, Garcia L et al (2015) In Silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS One 10:e0120058. https:\/\/doi.org\/10.1371\/journal.pone.0120058","journal-title":"PLoS One"},{"key":"2_CR133","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQKRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25:2561\u20132572. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"key":"2_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008348","volume":"4","author":"DA O\u2019Leary","year":"2009","unstructured":"O\u2019Leary DA, Sharif O, Anderson P et al (2009) Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening. PLoS One 4:e8348. https:\/\/doi.org\/10.1371\/journal.pone.0008348","journal-title":"PLoS One"},{"key":"2_CR135","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.1016\/j.nmd.2015.06.275","volume":"25","author":"N Naryshkin","year":"2015","unstructured":"Naryshkin N, Dakka A, Gabbeta V et al (2015) Small molecule compounds that promote exon skipping in the DMD gene. Neuromuscul Disord 25:S261. https:\/\/doi.org\/10.1016\/j.nmd.2015.06.275","journal-title":"Neuromuscul Disord"},{"key":"2_CR136","doi-asserted-by":"publisher","first-page":"164ra160","DOI":"10.1126\/scitranslmed.3005054","volume":"4","author":"GC Kendall","year":"2012","unstructured":"Kendall GC, Mokhonova EI, Moran M et al (2012) Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci Transl Med 4:164ra160. https:\/\/doi.org\/10.1126\/scitranslmed.3005054","journal-title":"Sci Transl Med"},{"key":"2_CR137","doi-asserted-by":"publisher","first-page":"10981","DOI":"10.1038\/ncomms10981","volume":"7","author":"G Han","year":"2016","unstructured":"Han G, Gu B, Cao L et al (2016) Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. Nat Commun 7:10981. https:\/\/doi.org\/10.1038\/ncomms10981","journal-title":"Nat Commun"},{"key":"2_CR138","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/archneurol.2008.540","volume":"66","author":"T Yokota","year":"2009","unstructured":"Yokota T, Takeda S, Lu Q-L et al (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66:32\u201338. https:\/\/doi.org\/10.1001\/archneurol.2008.540","journal-title":"Arch Neurol"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:04:23Z","timestamp":1780747463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":138,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_2","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}